Table 1. Clinical and biochemical features of two groups at baseline.
| Methylprednisolone-treated ACLF | Conservative managed ACLF | |
|---|---|---|
| Cases | 30 | 26 |
| Age (year) | 39.31±13.32 | 42.42±11.87 |
| Sex (male/female) | 23/7 | 20/6 |
| TBIL (µmol/l) | 393.12±133.27 | 395.42±174.38 |
| Creatinine (µmol/l) | 77.50±41.88 | 78.17±57.70 |
| PT (s) | 27.72±9.89 | 25.71±6.87 |
| PTA (%) | 31.18±9.94 | 33.27±6.46 |
| ALT (U/l) | 287.8 (26.2–3272.3) | 289.5 (15.9–313.1) |
| AST (U/l) | 233.9 (52.5–2521.0) | 284.1 (42.4–2859.3) |
| ALB (g/l) | 30.33±4.43 | 29.60±4.45 |
| MELD score | 24.36±6.49 | 23.03±5.93 |
| Encephalopathy (0/1/2/3/4) | 10/9/3/4/4 | 14/5/4/3/0 |
| Ascites (0/1/2/3) | 10/9/6/5 | 3/8/11/4 |
| Monocyte counts (/µl) | 819.81±624.69 | 888.43±450.26 |
| Lymphocyte counts (/µl) | 1205.36±618.48 | 1844.86±411.85 |
Abbreviations: ACLF, acute-on-chronic liver failure; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; PTA, prothrombin activity; TBIL: total bilirubin.
Values are expressed as mean±standard deviation (s.d.) or median (average).